Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry
Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry laboratories owned by NeoGenesis that enable the rapid screening of compounds that could be used to form new products. Epix hopes the deal will enable it to find new advanced MRI contrast agents.